Abstract
Objectives
Febrile Infection-Related Epilepsy Syndrome (FIRES) is a rare disorder characterized by refractory status epilepticus following febrile infections, affecting previously healthy children. This study aims to elucidate the limited therapeutic approaches for FIRES and presents a case study of an 8-year-old with intractable epilepsy, emphasizing the favorable response to anakinra during the chronic phase.
Materials and Methods
A comprehensive case report was conducted, detailing the patient's medical history, treatment regimen, and outcomes during anakinra therapy.
Results
Anakinra, initially administered during the acute phase in 2019, was temporarily discontinued after 29 days. In 2022, facing a chronic-phase exacerbation, the patient underwent a second course of anakinra treatment, demonstrating a notable positive impact on seizure activity. Over one year of anakinra therapy, a significant improvement in both seizure frequency and severity was observed.
Conclusions
This report contributes to existing evidence supporting the potential efficacy of anakinra in treating FIRES, particularly during the chronic phase. The presented case underscores the positive outcomes achieved with extended anakinra therapy, suggesting its continued benefits. The findings underscore the importance of further research to solidify anakinra's role in FIRES treatment and optimize its administration during different phases of the disorder.
Febrile Infection-Related Epilepsy Syndrome (FIRES) is a rare disorder characterized by refractory status epilepticus following febrile infections, affecting previously healthy children. This study aims to elucidate the limited therapeutic approaches for FIRES and presents a case study of an 8-year-old with intractable epilepsy, emphasizing the favorable response to anakinra during the chronic phase.
Materials and Methods
A comprehensive case report was conducted, detailing the patient's medical history, treatment regimen, and outcomes during anakinra therapy.
Results
Anakinra, initially administered during the acute phase in 2019, was temporarily discontinued after 29 days. In 2022, facing a chronic-phase exacerbation, the patient underwent a second course of anakinra treatment, demonstrating a notable positive impact on seizure activity. Over one year of anakinra therapy, a significant improvement in both seizure frequency and severity was observed.
Conclusions
This report contributes to existing evidence supporting the potential efficacy of anakinra in treating FIRES, particularly during the chronic phase. The presented case underscores the positive outcomes achieved with extended anakinra therapy, suggesting its continued benefits. The findings underscore the importance of further research to solidify anakinra's role in FIRES treatment and optimize its administration during different phases of the disorder.
| Original language | English |
|---|---|
| Pages | 15 -15 |
| Number of pages | 1 |
| Publication status | Published - 2024 |
| Externally published | Yes |
| Event | 17th Conference of Baltic Child Neurology Association - Jurmala , Latvia Duration: 23 May 2024 → 25 May 2024 Conference number: 17 https://www.bcna2024.lv/ |
Conference
| Conference | 17th Conference of Baltic Child Neurology Association |
|---|---|
| Country/Territory | Latvia |
| City | Jurmala |
| Period | 23/05/24 → 25/05/24 |
| Internet address |
Keywords*
- FIRES
Field of Science*
- 3.2 Clinical medicine
- 3.1 Basic medicine
Publication Type*
- 3.4. Other publications in conference proceedings (including local)